Text Size

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

This study has been completed.
Sponsor:
Collaborator:
Biogen Idec
Information provided by:
Sarah Cannon Research Institute
ClinicalTrials.gov Identifier:
NCT00193505
First received: September 12, 2005
Last updated: May 2, 2011
Last verified: May 2011
History of Changes
  Purpose

In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.


Condition Intervention Phase
Non-Hodgkins Lymphoma
 Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: Rituximab
Drug: 90Y Zevalin
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in the Treatment of Patients With Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Resource links provided by NLM:

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

Further study details as provided by Sarah Cannon Research Institute:

Primary Outcome Measures:
  • complete response rate

Secondary Outcome Measures:
  • progression-free survival
  • overall survival

Estimated Enrollment: 40
Study Start Date: October 2003
Study Completion Date: August 2005
Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
Detailed Description:

Upon determination of eligibility, patients will receive:

  • Ifosfamide + Carboplatin + Etoposide + Rituximab

Patients showing no response to this combination regimen will receive 90Y Zevalin after two cycles or when progression is clearly documented. In responding patients, four cycles will be administered, followed by 90Y Zevalin.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To be included in this study, you must meet the following criteria:

  • Intermediate grade CD20-positive B-cell non-Hodgkin's lymphoma
  • Persistent lymphoma after one or two previous chemotherapy regimens
  • Patients should not be considered candidates for high-dose chemotherapy
  • Ability to perform activities of daily living with assistance
  • Measurable or evaluable disease
  • Age > 18 years
  • Adequate bone marrow, liver and kidney function

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

  • Patients with impaired bone marrow reserve
  • Female patients who are pregnant or lactating
  • Serious active infection at the time of treatment
  • Any other serious underlying condition
  • Brain or meningeal) with lymphoma
  • HIV or AIDS-related lymphoma
  • Received external beam radiation therapy to > 25% of active bone marrow.
  • History of other cancers, either active or treated

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00193505

Locations
United States, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023
Sponsors and Collaborators
Sarah Cannon Research Institute
Biogen Idec
Investigators
Principal Investigator: John D. Hainsworth, MD Sarah Cannon Research Institute
  More Information

No publications provided

Responsible Party: John Hainsworth, MD, Sarah Cannon Research Institute
ClinicalTrials.gov Identifier: NCT00193505     History of Changes
Other Study ID Numbers: SCRI LYM 27, 106-P092
Study First Received: September 12, 2005
Last Updated: May 2, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Etoposide
Etoposide phosphate
Isophosphamide mustard
Rituximab
 Ifosfamide
Carboplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents

ClinicalTrials.gov processed this record on May 23, 2013